Emerging evidence and treatment paradigm of non-small cell lung cancer

Abstract

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice.

Background

Lung cancer is the leading cause of cancer-related deaths worldwide [1]. Previously, the only systemic antitumor therapy available was chemotherapy, which had modest efficacy and high toxicity. In recent years, small molecular tyrosine kinase inhibitors (TKIs) have emerged as promising treatment options [2] that lead to tumor regression. Non-small cell lung cancer (NSCLC) patients with driver gene mutations who are treated with TKIs have favorable survival outcomes and low toxicity [3, 4]. The development of epidermal growth factor receptor (EGFR)-TKIs has revolutionized the personalized treatment paradigm for NSCLC patients with EGFR mutations [5]. The median overall survival (OS) of such patients with advanced disease increased from < 10 months to almost 40 months [6, 7]. Immune checkpoint inhibitors (ICIs), such as programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors, destroy tumor cells via the PD-L1/PD-1 pathway and reactivate effector T cells [8]. The development of ICIs is also an important milestone in lung cancer treatment [9]. In patients without driver gene mutations, PD-L1/PD-1 inhibitors produce a durable clinical response and prolong long-term OS [10–12]. After all these years, EGFR-TKIs targeting the first druggable oncogene has evolved from first- to third-generation; furthermore, regulatory approvals have also been granted for agents directed against at least 9 another molecular targets. ICI monotherapy and combination therapy with chemotherapy have been approved for clinical use [13]. Here, we discuss the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy. In particular, studies conducted in China are also discussed to improve the generalizability of our findings and provide an important reference for studies conducted in other countries. Additionally, we have highlighted several clinical issues that should be explored by future studies.

Early-stage NSCLC

For the past 20 years, neoadjuvant or adjuvant chemotherapy has been recommended for patients with resectable NSCLC. However, the 5-year OS has improved by only 5% [14]. Novel adjuvant strategies are needed to optimize clinical outcomes after complete surgical resection in patients with early-stage NSCLC. A long-term survival benefit has been achieved with the use of EGFR-TKIs and ICIs in advanced NSCLC patients [6, 7, 11]. The treatment paradigm of such patients has changed significantly [15]. However, a few unresolved issues remain, including whether this success will be repeated in perioperative management of resectable NSCLC and how the treatment will be modified in the future. In this section, we review the results of important phase III clinical trials and propose unresolved clinical issues.

Emerging evidence with clinical implications

Adjuvant therapy with EGFR-TKIs

In the phase III ADAURA study, the third-generation EGFR-TKI osimertinib showed a clinically meaningful improvement in disease-free survival (DFS) in patients with resected EGFR-mutant NSCLC [16]. The risks of disease recurrence and death were reduced by 77% in patients with stage II–IIIA disease and by 73% in those with stage IB–IIIA disease. The survival benefit was greater in patients with more advanced disease, based on the eighth edition of the TNM classification (stage IB, hazard ratio [HR] = 0.44; stage II, HR = 0.33; stage IIIA, HR = 0.22) [17]. A DFS benefit was observed in patients treated with (HR = 0.29) or without (HR = 0.36) adjuvant chemotherapy, regardless of disease stage [18]. Despite the lack of data on OS, osimertinib was approved by the Food and Drug Administration (FDA) and other regulatory authorities as adjuvant therapy for patients with EGFR exon 19 deletion or the exon 21 L858R mutation [19].

Three phase III studies have shown conflicting findings regarding the use of first-generation EGFR-TKIs compared with chemotherapy as adjuvant treatment for resected EGFR-mutant NSCLC. The first one is the CTONG1104 study. A randomized phase III trial showed that adjuvant gefitinib, a first-generation EGFR-TKI, significantly prolonged the median DFS compared with chemotherapy (30.8 vs. 20.8 months) in patients with stage II–IIIA NSCLC harboring EGFR mutations [20]. The risk of recurrence or death was reduced by 44% (p = 0.001). However, the median OS was not significantly different between the gefitinib and chemotherapy groups over a median follow-up duration of 80 months (75.5 vs. 62.8 months; HR = 0.92; p  = 0.674) [21]. The EVIDENCE study compared adjuvant icotinib with chemotherapy for patients with stage II–IIIA EGFR-mutant NSCLC. After a median follow-up duration of 24.9 months, the median DFS was longer in the icotinib group than in the chemotherapy group (47.0 vs. 22.1 months; HR = 0.36; p  < 0.0001) [22]. Despite the lack of data on OS, the National Medical Products Administration approved icotinib as adjuvant treatment for patients with EGFR mutations after complete resection. The IMPACT study had a similar design to the CTONG1104 trial, which compared adjuvant gefitinib with chemotherapy for patients with resected stage II–IIIA NSCLC harboring EGFR mutations [23]. Although adjuvant gefitinib prevented early relapse, it did not prolong DFS or OS. The median DFSs were 35.9 and 25.1 months in the gefitinib and chemotherapy groups, respectively (HR = 0.92; p  = 0.63), whereas the median OS was not reached (HR = 1.03). Because the Kaplan–Meier curves overlapped at 3–4 years after surgery, adjuvant therapy with gefitinib was not approved for clinical use.

Adjuvant or neoadjuvant therapy with PD-1/PD-L1 inhibitors

IMpower010 was the first phase III trial to compare adjuvant immunotherapy with standard therapy for resected stage IB–IIIA NSCLC [24]. After adjuvant chemotherapy, atezolizumab group was associated with a significantly longer DFS compared with supportive care group. The risks of recurrence and death were reduced after atezolizumab treatment by 34% in stage II–IIIA NSCLC patients with ≥ 1% PD-L1 expression and by 21% in all stage II–IIIA NSCLC patients. The effect of atezolizumab on OS over a median follow-up duration of 32 months was unclear. On October 15, 2021, the FDA approved adjuvant atezolizumab following resection and platinum-based chemotherapy for patients with stage II–IIIA NSCLC and ≥ 1% PD-L1 expression in tumor cells; furthermore, the Ventana PD-L1 (SP263) assay was approved as a companion diagnostic device [25]. The IMpower010 study presented 46-month follow-up data for OS at the 2022 World Conference of Lung Cancer. Although the median OS was not reached, there was a trend toward prolonged OS after atezolizumab treatment in stage II–IIIA patients with ≥ 1% PD-L1 expression in tumor cells (HR = 0.71; 95% confidence interval [CI] = 0.49–1.03). A significant OS advantage was observed in patients with ≥ 50% PD-L1 expression in tumor cells (HR = 0.43; 95% CI = 0.24–0.78) [26].

KEYNOTE-091, the second clinical trial of adjuvant immunotherapy [27], enrolled patients with completely resected stage IB–IIIA NSCLC treated with pembrolizumab or placebo every 3 weeks for up to 18 cycles. Adjuvant chemotherapy was not mandatory for all patients and was recommended according to the local guidelines. The second interim analysis of KEYNOTE-091 was performed after a median follow-up duration of 35.6 months. The median DFS was longer in the pembrolizumab group compared with the placebo group (53.6 vs. 42.0 months; HR = 0.76; p = 0.0014). In patients with ≥ 50% PD-L1 expression in tumor cells, pembrolizumab did not prolong the DFS compared with the placebo (HR = 0.82; p = 0.14). In patients who received adjuvant chemotherapy, pembrolizumab prolonged the DFS by almost 2 years compared with the placebo (58.7 vs. 34.9 months; HR = 0.73; 95% CI = 0.60–0.89). On January 26, 2023, the FDA approved pembrolizumab as adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB–IIIA NSCLC [28].

Neoadjuvant therapies have several advantages, including reduction of tumor burden, which allows complete tumor resection, and evaluation of the pathological treatment response. CheckMate816 was the first phase III study that found favorable outcomes of neoadjuvant immunotherapy in patients with resectable stage IB–IIIA NSCLC [29]. The primary endpoint was pathological complete response (pCR) and event-free survival (EFS). Neoadjuvant nivolumab plus chemotherapy, compared with chemotherapy alone, significantly improved the pCR rate (24.0% vs. 2.2%; p  < 0.0001) and prolonged the EFS by 11 months (31.6 vs. 20.8 months; HR = 0.63; p  = 0.0052) after a median follow-up duration of 29.5 months. Most subgroups benefited from nivolumab plus chemotherapy compared with chemotherapy alone, and the interim analysis showed a favorable trend for OS (HR = 0.57; p  = 0.0079). Based on these results, neoadjuvant therapy with nivolumab plus chemotherapy was approved by the FDA on March 4, 2022, and by the National Medical Products Administration in January 2023 for patients with resectable NSCLC [30].

We summarize the shift in the treatment paradigm for early-stage NSCLC based on recently approved agents. We also present select ongoing trials with promising clinical implication in the next 5 years (Fig. 1, Table 1).

Fig. 1.

Treatment algorithm for resectable and unresectable NSCLC. Atezo, atezolizumab; nivo, nivolumab; pembro, pembrolizumab; durva, durvalumab; chemo, chemotherapy; CM816, CheckMate816; KN091, KEYNOTE-091

Table 1.

Ongoing trials for resectable earl-stage NSCLC patients that may change clinical practice in 5 years

Agents	Agent type	Control arm	Identification	status	NCT/Name	Sample size	Primary endpoint
Neoadjuvant + Adjuvant
Neoad: Nivolumab + chemo Adj: Nivolumab	PD-1 inhibitor	Placebo + chemo	Stage II–IIIB (N2)	Phase III	NCT04025879	452	EFS
Neoad: Atezolizumab + chemo *4C Adj: Atezolizumab*13C	PD-1 inhibitor	Placebo + chemo	Stage II–IIIB (N2)	Phase III	NCT03456063 (IMpower030)	453	EFS
Neoad: Toripalimab + chemo*3C Adj: Toripalimab + chemo*1C, Toripalimab*13C	PD-1 inhibitor	Placebo + chemo	Stage II–IIIB (N2)	Phase III	NCT04158440	406	MPR rate in stage III population; EFS in stage III population; MPR rate in stage II–III population;
Neoad: Tislelizumab + chemo Adj: Tislelizumab	PD-1 inhibitor	Placebo + chemo	Stage II–IIIA	Phase III	NCT04379635	453	MPR; EFS
Neoadjuvant
Arm1: Osimertinib + chemo Arm2: Osimertinib	EGFR-TKI	Placebo + chemo	Stage II–IIIB N2	Phase III	NCT04351555 (NeoADAURA)	328	MPR
Adjuvant
Arm1: Pembrolizumab + chemo*4C, pembrolizumab; Arm2: chemo*4C, pembrolizumab	PD-1 inhibitor	Chemo	Stage II–IIIB (N2)	Phase III	NCT04267848 (ALCHEMIST)	1210	DFS
Nivolumab + chemo*4C, nivolumab	PD-1 inhibitor	Chemo	Stage IB–IIIA	Phase III	NCT04564157 (NADIM-ADJUVANT)	210	DFS
Nivolumab + chemo	PD-1 inhibitor	Chemo + observation	Stage IB–IIIA	Phase III	NCT02595944 (ALCHEMIST-ANVIL)	903	DFS; OS
Durvalumab	PD-1 inhibitor	Placebo	Stage IB–IIIA	Phase III	NCT02273375	1415	DFS
Durvalumab + chemo	PD-1 inhibitor	Placebo + chemo	stage II–III NSCLC with MRD+	Phase III	NCT04385368 (MERMAID-1)	89	DFS
Osimertinib	EGFR-TKI	Placebo	Stage IA2–IA3	Phase III	NCT05120349 (ADAURA2)	380	DFS in high-risk stratum
Arm1: 6-month icotinib; Arm2: 12-month icotinib;	EGFR-TKI	Chemo	Stage II–IIIA	Phase III	NCT01996098 (ICTAN)	318	DFS
Arm1: Almonertinib + Chemo; Arm2: Almonertinib	EGFR-TKI	Chemo	Stage II–IIIA	Phase III	NCT04762459 (APEX)	606	DFS
Almonertinib	EGFR-TKI	Placebo	Stage II–IIIB (N2)	Phase III	NCT04687241	192	DFS
Gefitinib + chemo*4C, gefitinib	EGFR-TKI	Chemo	Stage II–IIIB (N2)	Phase III	NCT03381066	225	DFS
Alectinib	ALK-TKI	Chemo	Stage IB–IIIA	Phase III	NCT03456076 (ALINA)	257	DFS
Crizotinib	ALK-TKI	Observation	Stage IB–IIIA	Phase III	NCT02201992 (ALCHEMIST)	168	OS
Ensartinib	ALK-TKI	Placebo	Stage II–IIIB (N2)	Phase III	NCT05341583	202	DFS
Selpercatinib	RET-TKI	Placebo	Stage IB–IIIA	Phase III	NCT04819100	170	EFS

*Chemo chemotherapy, DFS disease-free survival, EFS event-free survival, MPR major pathological response, OS overall survival, pCR pathological complete response, TKI tyrosine kinase inhibitor, C cycles

Unresolved clinical issues

Prospective phase III studies have reported promising results. However, certain clinical issues remain unresolved. First, it is unclear whether adjuvant chemotherapy is necessary for all patients. Most trials of adjuvant treatment, such as CTONG1104 and EVIDENCE, have found beneficial effects of treatment with EGFR-TKIs plus chemotherapy in patients with resected NSCLC [21, 22]. However, the ADAURA study concluded that adjuvant chemotherapy should be administered on a case-by-case basis according to the decision of the patients and their physicians. Osimertinib was associated with prolonged survival compared with the placebo [16], with a lower HR (0.29 vs. 0.39), suggesting beneficial effects of chemotherapy [18]. To resolve this issue, future studies should compare investigational agents plus chemotherapy with investigational agents alone in a large number of patients to detect any differences [31]. Most ongoing clinical trials are using chemotherapy or chemotherapy plus placebo as the control arm. The ongoing APEX study is comparing the efficacy and safety of almonertinib plus chemotherapy, almonertinib alone, and chemotherapy alone for resected EGFR-mutant NSCLC [32].

Second, the effects of neoadjuvant therapy on pathological responses are unclear. Immunotherapy has a unique antitumor mechanism of action. When the checkpoint pathway is blocked, tumor-infiltrating lymphocytes and macrophages enter the tumor nest, leading to tumor progression based on RECIST assessment [33] and a major pathological response (MPR) or pCR. Thus, the pathological response is an early therapeutic indicator for neoadjuvant therapy after complete resection and guides treatment decisions. A previous study found that homologous recombination deficiency was associated with the neoadjuvant immunotherapy response in lung cancer [34]. Improvements in MPR and pCR rates were associated with longer EFS and DFS [35–37]. However, it is unclear whether the MPR or pCR rate indicates a survival benefit. Although several phase III neoadjuvant trials used MPR as a primary endpoint, further studies are needed to confirm their results.

Third, it is unclear whether the molecular residual disease (MRD) status determined by liquid biopsy can guide the selection of personalized adjuvant therapy. The MRD status can be determined by sequencing circulating tumor DNA in peripheral blood samples to predict disease recurrence and distant metastasis [38]. The baseline MRD status within 1 month after surgery can be used to stratify patients into high- and low-risk groups [39]. Furthermore, longitudinal MRD surveillance can identify patients with potential to be cured by resection, resulting in a negative predictive value of 96.8% [40]. Additionally, the positive status of MRD can predict disease recurrence 3–5 months earlier than can imaging [41]. Dynamic MRD monitoring after surgery provides treatment guidance regarding the risk of disease recurrence or metastasis. Previous studies have shown that consolidation treatment with ICIs improved the clinical outcomes of patients with MRD [42]. Patients with EGFR-mutant advanced disease with MRD negative status after local treatment or tumor burden on imaging may undergo an EGFR-TKI “drug holiday” [43]. However, further studies are needed to determine whether personalized adjuvant therapy can be selected based on the MRD status. Multiple clinical trials with novel designs, such as FATES/CTONG2105, have reported promising results [44]. Accumulation of further evidence may affect the use of adjuvant therapy for early-stage NSCLC.

Fourth, it is also unclear whether adjuvant targeted therapy against rare genetic variants is effective. Rare genetic variants, such as anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) fusion, have low prevalence and druggability [45]. Chemotherapy and immunotherapy with ICIs have moderate efficacy but high toxicity [46, 47]. Treatment with effective TKIs has changed the treatment paradigm for patients with advanced NSCLC harboring rare genetic variants [48–50]. Tables 1 and 2 summarize the ongoing prospective clinical trials of targeted therapy in patients with rare genetic variants who have undergone resection. The ALINA study, which will compare adjuvant alectinib with adjuvant chemotherapy in patients with ALK fusion genes, has completed patient enrollment [51]. Its results may impact future clinical treatment of patients.

Table 2.

Ongoing trials for unresectable stage III NSCLC patients that may change clinical practice in 5 years

Agents	Agent type	Control arm	Status	Chemo-radiotherapy	NCT/Name	Sample size	Primary endpoint
Arm1:TQB2450 + Anlotinib Arm2: TQB2450	PD-L1 inhibitor	Placebo	Phase III	cCRT/sCRT	NCT04325763	315	PFS
Arm1: Durvalumab + Oleclumab; Arm2: Durvalumab + Monalizumab	PD-L1 inhibitor; CD73 inhibitor; NKG2A inhibitor	Durvalumab + Placebo	Phase III	cCRT	NCT05221840 (PACIFIC-9)	999	PFS
Durvalumab + Domvanalimab	PD-L1 inhibitor; TIGIT inhibitor	Durvalumab + Placebo	Phase III	cCRT	NCT05211895 (PACIFIC-8)	860	PFS
Durvalumab	PD-L1 inhibitor	Placebo	Phase III	cCRT/sCRT	NCT03706690 (PACIFIC-5)	407	PFS
Durvalumab + cCRT → durvalumab	PD-L1 inhibitor	Placebo	Phase III	cCRT	NCT03519971 (PACIFIC-2)	328	PFS
Arm1: Pembrolizumab + cCRT → pembrolizumab; Arm2:Pembrolizumab + cCRT →  pembrolizumab + Olaparib	PD-1 inhibitor; PARP inhibitor	Durvalumab	Phase III	cCRT	NCT04380636 (KEYLYNK-012)	870	PFS; OS
Pembrolizumab + vibostolimab + cCRT → pembrolizumab + vibostolimab;	PD-1 inhibitor; TIGIT inhibitor	Durvalumab	Phase III	cCRT	NCT05298423 (KEYVIBE-006)	784	PFS; OS; PFS + OS (PD-L1 ≥ 1%);
Arm1: Nivolumab + cCRT →  nivolumab + ipilimumab Arm2: Nivolumab + cCRT →  nivolumab	PD-1 inhibitor; CTLA-4 inhibitor	Durvalumab	Phase III	cCRT	NCT04026412 (CheckMate73L)	888	PFS
Atezolizumab + tiragolumab	PD-L1 inhibitor; TIGIT inhibitor	Durvalumab	Phase III	cCRT	NCT04513925 (SKYSCRAPER-03)	800	PFS
Osimertinib	EGFR-TKI	Placebo	Phase III	cCRT/sCRT	NCT03521154 (LAURA)	216	PFS
Almonertinib	EGFR-TKI	Placebo	Phase III	cCRT/sCRT	NCT04951635	150	PFS
Arm1: Alectinib Arm2: Entrectinib Arm3: Pralsetinib	ALK-TKI; ROS1-TKI; RET-TKI	Durvalumab	Phase I-III	cCRT/sCRT	NCT05170204	320	PFS
MRD+: Durvalumab+ Chemotherapy; MRD−: Durvalumab	PD-L1 inhibitor	–	Phase II	cCRT	NCT04585490	48	The change of ctDNA (MRD+) due to the addition of chemotherapy

PFS progression-free survival; cCRT/sCRT concurrent/sequential chemotherapy and radiotherapy; OS overall survival; TKI tyrosine kinase inhibitor; MRD molecular residual disease; ctDNA circulating tumor DNA

Localized NSCLC

Patients with stage III NSCLC are a highly heterogenous population. Approximately one-third of these patients survive for 5 years, and most have N2 disease and metastasis [52]. These patients have unresectable, resectable, or potentially resectable tumors [53]. In clinical practice, stage III patients with unresectable disease are treated with definitive chemoradiotherapy. We present emerging evidence with clinical implications, summarize the ongoing clinical trials that may change clinical practice in the next 5 years, and highlight the unresolved clinical issues to be addressed.

Emerging evidence with clinical implications

The PACIFIC trial was the first to impact the clinical treatment of stage III NSCLC patients with unresectable disease. This phase III study compared consolidation therapy with durvalumab and placebo in patients with stage III NSCLC after concurrent chemoradiotherapy [54]. Based on the initial results, on February 16, 2018, the FDA approved durvalumab for patients with unresectable stage III NSCLC following concurrent platinum-based chemotherapy and radiation therapy [55]. The detailed results, published 5 years after the last patient was randomized [12], showed median progression-free survival (PFS) times of 16.9 and 5.6 months in the durvalumab and placebo groups, respectively (HR = 0.55; 95% CI = 0.45–0.68). The 5-year PFS rates were 33.1% and 19.0% in the durvalumab and placebo groups, respectively, indicating that one-third of patients receiving durvalumab were disease-free in 5 years. The median OS times were 47.5 and 29.1 months, and the 5-year OS rates were 42.9% and 33.4%, in the durvalumab and placebo groups, respectively (HR = 0.72; 95% CI = 0.59–0.89). These results have significant implications for unresectable stage III patients. Consistent with previous reports, OS and PFS benefits with durvalumab compared with placebo were observed in all prespecified subgroups. However, given the small sample size, it is uncertain whether durvalumab is associated with a survival benefit in patients with EGFR mutations or ALK fusion.

Gemstone-301 is a phase III study that compared PFS between sugemalimab and placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III NSCLC in China. Patients were excluded if they had sensitive EGFR, ALK, or ROS1 gene alterations. According to the interim results, consolidation therapy with sugemalimab resulted in a statistically and clinically significant prolongation of the median PFS (9.0 vs. 5.8 months) and reduction of recurrence risk by 36% compared with placebo [56] in all patients as well as in the predefined subgroups. Based on these results, on June 6, 2022, sugemalimab was approved in China for the treatment of unresectable stage III NSCLC without progression after concurrent or sequential chemoradiotherapy. Subsequent results of Gemstone-301 showed median PFS times after sugemalimab and placebo treatment of 10.5 and 6.2 months (HR = 0.65), respectively, for both sequential and concurrent chemoradiotherapy; 8.1 and 4.1 months (HR = 0.57), respectively, for sequential chemoradiotherapy; and 15.7 and 8.3 months (HR = 0.71), respectively, for concurrent chemoradiotherapy [57]. The OS in the sugemalimab and placebo groups was inconclusive (not reached vs. 25.9 months) after median follow-up durations of 27.1 and 23.5 months, respectively.

After the approval of durvalumab for stage III disease, the PACIFIC-R study was initiated as an international retrospective trial to assess its real-world effectiveness. Patients received consolidation therapy with durvalumab after concurrent or sequential chemoradiotherapy. The primary end points were investigator-assessed real-word PFS (rwPFS) and OS. After a median follow-up of 23.5 months, durvalumab achieved a median rwPFS of 21.7 months and 3-year OS rate of 63.2%. In line with the results of Gemstone-301, survival benefit could also be achieved in patients treated with sequential chemoradiotherapy, with a median rwPFS of 19.3 months; rwPFS was longer in patients with PD-L1 expression ≥ 1% versus < 1% (22.4 vs. 15.6 months) [58].

Based on the aforementioned results, we summarize the current and future changes in the treatment of unresectable stage III NSCLC patients, including those based on trials that led to drug approval (Fig. 1). The ongoing trials are summarized in Table 2.

Unresolved clinical issues

The role of induction therapy in unresectable stage III NSCLC is unclear. Neoadjuvant chemotherapy has moderate efficacy in disease downstaging (reduction of disease stage from baseline), with a pCR rate of only 5–10% [59, 60]. Treatment with ICIs improved the pCR rate to 10–30% and MPR rate to 30–50% [35, 36, 61]. The Checkmate816 trial showed greater pathological regression (pCR rate: 24.0% vs. 2.2%), clinical response (OR: 54% vs. 37%), and radiographic downstaging (31% vs. 24%) in the nivolumab plus chemotherapy group compared with the placebo group [29]. Thus, neoadjuvant therapy may convert disease status from unresectable to resectable in patients with stage III NSCLC. However, most clinical trials did not administer induction therapy for unresectable stage III patients. A phase II study (NCT04580498), enrolling 107 patients, found that SHR-1701, a PD-L1/TGF-β antibody, is safe and effective for unresectable stage III NSCLC [62]. The patients were treated with induction therapy involving three cycles of SHR-1701 with or without chemotherapy before surgery or definitive chemoradiotherapy, followed by maintenance therapy with 16 cycles of SHR-1701. The post-induction and best overall objective response (ORR) rates were 56.1% and 70.1%, respectively. The median EFS was 18.2 months. In accordance with the decision of the multidisciplinary team, one-fourth of the patients received surgery; these patients had MPR and pCR rates of 44.4% and 25.9%, respectively; the median EFS was not reached. These results suggest that some patients may develop resectable disease from unresectable disease and have improved survival. A similar ongoing study, APPRAOCH/CTONG2101, used almonertinib as induction and maintenance therapy for EGFR-mutant stage III NSCLC [63]; its results are awaiting.

The optimal management of unresectable stage III NSCLC with actionable genetic alterations is unclear. In the PACIFIC trial, patients were selected based on their genomic profile. Forty-three patients with EGFR-mutant NSCLC were included in the durvalumab (n = 29) and placebo (n = 14) groups. Subgroup analysis according to the EGFR mutation status failed to show significant differences due to the small sample size [54]. In a retrospective study by Hellyer et al. [47], stage III NSCLC patients were treated with durvalumab as consolidation therapy following definitive chemoradiation. Patients with EGFR or human epidermal growth factor receptor 2 (HER2) mutations had a shorter DFS compared with patients with the wild-type genes (7.5 months vs. not reached; p = 0.04). These results suggest that locally advanced NSCLC with EGFR or HER2 mutations are unlikely to benefit from ICIs [64] because of the uninflamed tumor microenvironment [65]. Therefore, NSCLC with actionable genes should be treated with durvalumab cautiously. LAURA is a phase III study comparing osimertinib with placebo following chemoradiotherapy for EGFR-mutant NSCLC [66]. A phase I–III umbrella study (NCT05170204) evaluated the efficacy and safety of an ALK-TKI, ROS1-TKI, and rearranged during transfection–TKI in patients with unresectable stage III NSCLC according to their biomarker status [67].

It is unclear whether the new treatments should be added during chemoradiotherapy or maintenance therapy for stage III NSCLC. Durvalumab and sugemalimab should be administered as maintenance therapy after definitive chemoradiotherapy. Most trials, such as PACIFIC-8, PACIFIC-9, and SKYSCRAPER-03, have followed the study design of the PACIFIC study using novel agents or combination therapy with durvalumab administered to the control arm [68–70]. Some clinical trials, such as KEYVIBE-006, KEYLYNK-012, and CheckMate73L, added a PD-1 inhibitor or another ICI to concurrent chemoradiotherapy and used monotherapy or combined therapy as maintenance therapy [71–73]. Further studies are needed to determine the toxicity of these agents with chemoradiotherapy.

Advanced-stage NSCLC

Approximately 60% of patients with NSCLC have locally advanced or advanced disease at the time of diagnosis [74] and thus are not eligible for curative treatment. Molecular characterization of advanced NSCLC has resulted in an established treatment paradigm that targets well-characterized oncogenes, including EGFR, ALK, ROS1, RET, mesenchymal–epithelial transition factor exon 14 skipping (MET^{14 skipping}), and V-Raf murine sarcoma viral oncogene homolog B p.V600E (BRAF^V600E) alterations [75]. Patients without druggable oncogenes are treated with monotherapy or combination therapy with ICIs that target PD-1/PD-L1 [76, 77]. Recently, the range of actionable alterations has been expanded to include Kirsten rat sarcoma viral oncogene homolog G12C (KRAS^G12C), neurotrophic tyrosine receptor kinase (NTRK) 1, and HER2 due to the approval of new therapies. The novel ICIs and their combinations are also being used to treat patients with brain metastasis. We discuss emerging evidence that has modified the current treatment paradigm for advanced NSCLC (Fig. 2). We also discuss the main unresolved clinical issues and ongoing clinical trials that may impact clinical practice in the next 5 years (Table 3).

Fig. 2.

Treatment algorithm for advanced NSCLC. Larotrec, larotrectinib; entrec, entrectinib; pembro, pembrolizumab; atezo, atezolizumab; cemip, cemiplimab; toripa, toripalimab; nivo, nivolumab; ipili, ipilimumab; durva, durvalumab; atezo, atezolizumab; tirago, tiragolumab; treme, tremelimumab; sinti, sintilimab; tisle, tislelizumab; camre, camrelizumab; serplu, serplulimab; suge, sugemalimab; chemo, chemotherapy

Table 3.

Ongoing trials of advanced NSCLC that may change clinical practice in 5 years

Oligometastases
Therapeutic regimens	Status	NCT No	Sample size	Primary endpoint
Standard medical therapy ± surgery/RT	Phase III	NCT03827577 (OMEGA)	195	OS
Chemotherapy/erlotinib/pembrolizumab ± RT	Phase II/III	NCT03137771 (NRG-LU002)	400	PFS/OS
Systemic anti-cancer therapy ± RT	Phase III	NCT02417662 (SARON)	340	OS
Standard of Care ± RT	Phase II/III	NCT02759783 (CORE)	206	PFS
osimertinib ± LCT	Phase II	NCT03410043 (NORTHSTAR)	143	PFS
Brigatinib + LCT	Phase I	NCT03707938 (BRIGHTSTAR)	35	Incidence of adverse events
ipilimumab + nivolumab ± LCT	Phase III	NCT03391869 (LONESTAR)	360	OS

KRAS
KRASG12C inhibitors	Drug type	Status	NCT No	Sample size	Primary endpoint
KRAS inhibitor monotherapy
Sotorasib	KRAS G12C inhibitor	Phase III	NCT04303780 (CodeBreaK200)	345	PFS
Adagrasib	KRAS G12C inhibitor	Phase III	NCT04685135 (KRYSTAL-12)	340	PFS
JDQ443	KRAS G12C inhibitor	Phase Ib/II Phase III	NCT04699188 (KontRASt-01) NCT05132075 (KontRASt-02)	425; 360	DLT, AE, SAE, dose interruptions and reductions, dose intensity, ORR; PFS
D-1553	KRAS G12C inhibitor	Phase I/II	NCT04585035 (D1553-101) NCT05383898	200 203	DLT, AE, Plasma concentration; DLT, AE, ORR
GDC-6036	KRAS G12C inhibitor	Phase Ia/b Phase II/III	NCT04449874 (GO42144) NCT03178552 (BFAST-cohort G)	498 1000 (all cohorts)	AE, DLT; PFS
Combination with KRAS inhibitors
Sotorasib + RMC-4630	KRAS G12C; SHP2 inhibitor	Phase II	NCT05054725	46	ORR
Sotorasib/Adagrasib + TNO155	KRAS G12C; SHP2 inhibitor	Phase I/II	NCT04185883 (CodeBreak101) NCT04330664 (KRYSTAL-2)	1054 (all cohorts) 86	DLT, TEAE, AE, vital signs, ECG, laboratory test values, ORR; AE, Plasma concentration
Adagrasib + pembro	KRAS G12C; immune checkpoint inhibitor	Phase II	NCT04613596 (KRYSTAL 7)	250	ORR
Adagrasib + BI1701963	KRAS G12C; SOS1 inhibitor	Phase I/Ib	NCT04975256 (KRYSTAL 14)	100	TRAE, Plasma concentration, DLT

NTRK
TRK inhibitors	Drug type	Status	NCT No	Sample size	Primary endpoint
Selitrectinib	Next generation TRK inhibitor	Phase I/II	NCT03215511	81 (adult and pediatric patients)	MTD, recommended dose, ORR
Repotrectinib	Next generation TRK /ROS1 inhibitor	Phase I/II	NCT04094610 NCT03093116 (TRIDENT-1)	75 (adult and pediatric patients); 500 (all arms)	DLT, ORR; DLT, RP2D, ORR

HER2
HER2 inhibitors	Drug type	Status	NCT No	Sample size	Primary endpoint
T-DXd	ADC	Phase II Phase III	NCT04644237 (DESTINY-Lung02) NCT05048797 (DESTINY-Lung04)	150 264	ORR PFS
T-DM1	ADC	Phase II	NCT02675829	140	ORR
A166	ADC	Phase I/II	NCT03602079	49	MTD
Pyrotinib	TKI	Phase III	NCT04447118 (PYRAMID-1)	150	PFS
Poziotinib	TKI	Phase III	NCT05378763 (PINNACLE)	268	PFS

ADC
ADC agents	ADC targets	Status	NCT No	Sample size	Primary endpoint
HER3-DXd	HER3	Phase II Phase I	NCT04619004 (HERTHENA-Lung01) NCT03260491	420 264	ORR; DLT, AE, ORR, maximum serum concentration, area under the serum concentration–time curve
ABBV-399	C-MET	Phase II Phase III	NCT03539536 NCT04928846	270 698	ORR, AE; PFS, OS
IMMU-132	TROP-2	Phase II Phase III	NCT03964727 (TROPICS-03) NCT05089734	165 520	ORR; OS
DS-1062	TROP-2	Phase III	NCT04656652 (TROPION-LUNG01)	590	PFS, OS
SAR408701	CEACAM5	Phase III	NCT04154956 (CARMEN-LC03)	554	PFS, OS
SAR408701 + ramucirumab	CEACAM5; Immune checkpoint inhibitor	Phase II	NCT04394624 (CARMEN-LC04)	36	DLT, ORR
SAR408701 + pembro	CEACAM5; Immune checkpoint inhibitor	Phase II	NCT04524689 (CARMEN-LC05)	120	DLT

ICI for oncogene-negative NSCLC
PD-1/PD-L1 inhibitor	Drug type	Status	NCT No	Sample size	Primary endpoint
Atezo + tirago	Anti-PD-L1; anti-TIGIT	Phase III	NCT04294810 (SKYSCRAPER-01)	635	PFS, OS
Pembro + MK-7684a	Anti-PD-1; anti-TIGIT	Phase III	NCT04738487 (MK-7684A-003)	1246	OS (stratified by PD-L1 expression)
Pembro + Eftilagimod alpha	Anti-PD-1; anti-LAG3	Phase II	NCT03625323 (TACTI-002)	189	ORR
Pembro + Lenvatinib + chemo	Anti-PD-1; anti-VEGF	Phase III	NCT03829319 (LEAP-006)	726	DLT, AE, PFS, OS
Pembro + Lenvatinib	Anti-PD-1; anti-VEGF	Phase III	NCT03976375 (LEAP-008)	405	OS, PFS

RT radiotherapy, LCT local consolidation therapies, PFS progression-free survival, OS overall survival, DLT dose-limiting toxicity, AE adverse event, SAE serious adverse event, ORR objective response rate, TEAE treatment emergent adverse events, MTD maximum tolerated dose, RP2D recommended phase II dose, ADC antibody-drug conjugate

Oligometastases

Emerging evidence with clinical implications

The oligometastasis hypothesis, initially proposed by Hellman and Weichselbaum in 1995 [78], suggests a restricted metastatic state. Oligometastases were traditionally defined based on imaging features and the number and size of metastases: no more than five metastatic sites with an indolent biology [79, 80]. However, this definition lacked specificity, which led to significant heterogeneity in the prognosis and 5-year OS rate (8.3–86%) of NSCLC [81].

Recently, consensus between the European Society for Therapeutic Radiology and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) [82], as well as consensus between the ESTRO and American Society of Radiation Oncology (ASTRO) [83], suggested that the spectrum of oligometastases should include distinct states based on clinical characterizations, including time to first detection and treatment response. The new classification incorporated independent prognostic factors and is being evaluated in prospective studies (ESTRO, EORTC, and OligoCare) [84]. But the oligometastatic spectrum should still be classified from the perspective of precision medicine based on the underlying biological characteristics of the tumor and immune contexture.

Recent evidence from several phase II randomized controlled trials of NSCLC patients suggests that the addition of local consolidation therapy (LCT) to systemic therapy for oligometastatic NSCLC prolongs the PFS and OS and may even be curative for some patients [80]. Gomez et al. [85, 86] found that local therapy (radiotherapy or surgery) administered after induction chemotherapy prolonged the median PFS (14.2 vs. 4.4 months; p = 0.022) and OS (41.2 vs. 17.0 months; p = 0.017) compared with those without LCT. The median time to appearance of new metastasis was higher in the LCT group than the control group (11.9 vs. 5.7 months; p = 0.0497). Similar to Gomez et al. [85, 86], Iyengar et al. [87] found beneficial effects of LCT after systemic chemotherapy. Another study of EGFR-mutant NSCLC patients administered first-generation EGFR-TKIs and upfront radiotherapy for both the primary and metastatic sites reported a significantly prolonged median PFS (20.2 vs. 12.5 months; p < 0.001) and OS (25.5 vs. 17.4 months; p < 0.001) compared with those without radiotherapy [88]. Based on these results, several guidelines, including those published by European Society of Medical Oncology and The National Comprehensive Cancer Network, have recommended surgery or radiotherapy for the management of oligometastatic disease [89, 90]. New treatment paradigm was thus established in this regard.

Unresolved clinical issues

It is unclear whether any specific patient subgroups benefit from LCTs. The benefit of local therapy was observed in oligometastatic cancers of various histological subtypes in the phase II SABR COMET trial [91]. By contrast, another phase II trial of breast cancer (CURB) showed no effect of stereotactic body radiotherapy on PFS in oligoprogressive disease, whereas a substantial response was observed in the NSCLC cohort [92]. Therefore, predictive biomarkers of the response to LCTs are needed. Advancements in liquid biopsy, imaging technology, and tumor biology may allow the role of LCT to be evaluated in different oligometastatic states and determination of the potential safety of de-escalation or omission of systemic therapy. Results from confirmatory randomized trials are expected to prompt changes in future clinical guidelines (Table 3). Furthermore, because TKIs (such as osimertinib and alectinib for EGFR/ALK-positive patients) and ICIs (for driver mutation-negative patients) have shown durable control of lung cancer, further studies are required to explore the effectiveness of local therapy with newer systemic therapies for oligometastases. Several ongoing trials have explored these unresolved issues, and their results are awaited (Table 3).

KRAS^G12C

Emerging evidence with clinical implications

KRAS, a mutated oncogene, was first identified in 1967 and has long been considered “undruggable” [93]. KRAS mutations occur in 25–30% of lung adenocarcinomas. The G12C variant (i.e., change from glycine to cysteine) accounts for 39% of KRAS mutations, whereas the G12D variant (i.e., change from glycine to aspartic acid) accounts for 17% [94–96]. Approximately 10% of Chinese patients with NSCLC have KRAS mutations, which is a lower proportion than that in the Western population. Of these patients, nearly 30% have the KRAS^G12C mutation [97]. In 2013, a new pocket was identified in which mutant KRAS protein binds to GDP near the effector binding switch II area; the identification of this pocket allows KRAS^G12C to be targeted for the treatment of KRAS^G12C-mutant NSCLC [98]. Then, a new stage has been set for the treatment of KRAS^G12C-mutated NSCLC.

Two trials have targeted KRAS^G12C using sotorasib and adagrasib. In the phase II CodeBreaK100 trial, 124 KRAS^G12C mutated, previously treated patients with NSCLC were treated with sotorasib and updated results showed an ORR of 41%, median PFS of 6.3 months, and median OS of 12.5 months [99]. Sotorasib was more effective than standard therapy with docetaxel, which prompted the FDA to approve it as the first KRAS inhibitor. Furthermore, the phase III CodeBreak 200 trial was initially for confirmatory purpose but failed to do so. It has just reported to meet its primary endpoint of PFS comparing sotorasib with docetaxel (PFS, median 5.6 and 4.5 months, respectively (p = 0.002) [100]. However, there was no difference in the median OS between the two treatment arms (10.6 vs. 11.3 months; p = 0.53). Another phase II trial, KRYSTAL-1, found similar results in 116 patients with KRAS^G12C-mutant NSCLC [101] who were treated with adagrasib as second- or later-line therapy. The ORR was 42.9%, median PFS was 6.5 months, and median OS was 12.6 months. Thus, adagrasib just became the second KRAS inhibitor approved by the FDA. Although sotorasib and adagrasib have similar antitumor effects, intracranial response is still a black box for sotorasib. Adagrasib seemed to step further by presenting its effectiveness in controlling intracranial disease [102]. A retrospective subgroup analysis in KRYSTAL-1 showed an intracranial ORR of 33% and median intracranial PFS of 5.4 months for treated central nervous system (CNS) metastases evaluated using the RANO-BM criteria [101]. A similar intracranial ORR of 32% was observed for untreated CNS metastases [103]. These data suggest comparable control of intracranial and systemic disease by adagrasib. These results, new treatment options of targeted therapy for KRAS^G12C already become available for clinical use and a new era is coming (Fig. 2).

Unresolved clinical issues

Although several new KRAS^G12C inhibitors have been developed, some clinical issues remain to be resolved. The results of CodeBreak 200 don’t finally serve its initially confirmatory purpose because of the small magnitude of improvement in OS by sotorasib. This may be because of the heterogeneous genetic characteristics of KRAS [104]. The rat sarcoma virus pathway and KRAS biology are more complex than receptor tyrosine kinase (RTK) drivers, as indicated by their resistance mechanisms to sotorasib and adagrasib, including secondary KRAS mutations, bypass activation of the RTK/RAS signaling pathway, co-existing mutations, histological transformation, and immunological adaptation [105]. These results suggest that monotherapy has limited efficacy. The need to obtain a prolonged response and overcome these resistance mechanisms with acceptable safety highlights the need for more potent KRAS^G12C inhibitors and combination strategies. Until now, at least 13 KRAS^G12C inhibitors have been evaluated in trials. Of these, several (e.g., JDQ443 and GDC-6036) are highly selective and have shown promising results. The combination of KRAS inhibitors with other targeted inhibitors may prevent or delay the emergence of resistance by targeting more than one oncogenic pathway. Furthermore, because KRAS variants and co-mutations are related to the efficacy of ICIs [106, 107], combinations of KRAS inhibitors and ICIs are also being investigated (Table 3). Some of these strategies may become upfront choices for advanced KRAS-driven NSCLC in the future.

NTRK

Emerging evidence with clinical implications

NTRK fusion genes were first identified to be oncogenic in colorectal tumors in 1982 [108]. Since then, NTRK1–3 fusion genes have been identified in several tumor types and are present in < 1% of NSCLC cases [109]. NTRK alterations are present in 0.59% of Chinese patients with NSCLC [110]. The identification of NTRK as an oncogenic driver has prompted studies of targeted therapy against tyrosine receptor kinase (TRK) fusion genes.

Several clinical trials have shown that NTRK fusion genes are sensitive to certain TKIs in adult and pediatric tumors, including NSCLC. The first-generation TRK inhibitors larotrectinib and entrectinib received tumor-agnostic approval by the FDA in 2018 and 2019, respectively. The antitumor activity of larotrectinib was investigated in a pooled analysis of several phase I and II trials of solid tumors. Its efficacy in lung cancers with TRK fusion genes was comparable with that in other histological types of cancers. The ORR and median PFS were 73% and 35.4 months for lung cancer [111] and 69% and 29.4 months for solid tumors [112], respectively. Entrectinib also demonstrated a durable systemic response, with an ORR of 61.3% and a median PFS of 13.8 months [113]. Both drugs demonstrated CNS activity. An integrated analysis of patients with lung cancer and CNS metastases showed an ORR of 63% with larotrectinib versus 67% with entrectinib [114–116]. Thus, TRK inhibitors that target NRTK fusion genes are effective for the treatment of lung cancers (Fig. 2).

Unresolved clinical issues

The treatment paradigm for NTRK fusion gene-positive lung cancer is similar to that for cancers expressing other oncogenes. Resistance to TRK inhibitors is inevitable and is mediated by on-target resistance, NTRK kinase domain mutations, and off-target resistance, such as MET amplification and BRAF or KRAS mutations [117]. To overcome on-target resistance, next-generation TRK inhibitors are needed. Several new agents are under investigation, of which selitrectinib and repotrectinib had the most promising results in early reports (ORR = 45% vs. 50%) [118, 119] (Table 3). Another agent, PBI-200, has higher brain penetrance; however, the results of its efficacy are awaiting. ICP-723 is a potent next-generation TRK inhibitor developed by Chinese investigators and is highly active against resistance mutations (e.g., NTRK G595R, F589L, and G667C/A/S) (NCT04685226). Future studies should evaluate strategies to inhibit off-target resistance pathways.

HER2

Emerging evidence with clinical implications

Mutations in the HER2 oncogene were first identified in 2004 [120] and account for approximately 1–4% of NSCLC cases [121]. The HER2 alterations that drive tumor development are HER2 mutations (2–4%), amplification (FISH copy number ≥ 2; 10–20%), and protein overexpression (immunohistochemical score of 2+/3+; 2.4–38%) [122, 123]. The predominant HER2 mutation in NSCLC is A775_G776insYVMA in exon 20 (80–90%) [124]. Strategies that target HER2 alterations are effective for other cancers, such as breast cancer; however, they have produced conflicting results in NSCLC.

In the past two decades, several anti-HER2 therapies, including monoclonal antibodies, chemotherapy, TKIs, and antibody–drug conjugates (ADCs), have been reported. Pan-HER2-TKIs, such as afatinib, neratinib, and dacomitinib, showed no benefit for NSCLC [125–127]. Selective HER2-TKIs, such as pyrotinib, mobocertinib, and poziotinib, had moderate efficacy as second- or later-line therapies, with ORRs of 20–30% [128, 129]. However, inhibition of HER2 activity by HER2-TKIs is limited by their high toxicity. Thus, HER2-TKIs are used only as second- or later-line treatments. Combination of the HER2 antibodies trastuzumab and pertuzumab with versus without docetaxel produced a similar response rate of 21–29% [130].

Recently, promising data have been reported for anti-HER2 ADCs. The first ADC, trastuzumab emtansine (T-DM1), was more effective for lung cancer than were previous treatments that targeted HER2 mutations, with an ORR of 44% and median PFS of 5 months [131]. Based on the engineering mechanism of T-DM1, trastuzumab deruxtecan (DS-8201) was developed by switching the payload and enabling the bystander effect, leading to the highest clinical activity yet [132]. The phase II DESTINY-Lung01 trial included 91 patients with HER2-mutated, treated NSCLC who received DS-8201 and reported an ORR of 55%, median PFS of 8.2 months, and median OS of 17.8 months [133]. Similar responses were observed for all HER2 mutations regardless of the gene amplification or protein expression status or presence of CNS metastasis. Another phase I trial of DS-8201 demonstrated a higher ORR of 72.7% and a median PFS of 11.3 months in the NSCLC group [134]. Based on the phase II randomized DESTINY-LUNG02 trial, which showed an ORR of 53.8% in previously treated HER2-mutant NSCLC (NCT04644237) [135], the FDA has recently granted accelerated approval to DS-8201 for treatment of previously treated HER2-mutant NSCLC. Therefore, a new standard of care was established for patients with NSCLC harboring HER2 mutations (Fig. 2).

Unresolved clinical issues

Several clinical issues regarding novel therapies for HER2-mutant NSCLC remain unresolved. First, it is unclear whether DS-8201 is effective as first-line treatment. First-line treatment with DS-8201 is being investigated in the DESTINY Lung04 trial (NCT05048797). Second, there is limited evidence on the mechanisms underlying resistance to targeted therapy and ADCs. Therefore, future studies should explore strategies to overcome resistance. Third, the CNS activity of emerging anti-HER2 drugs was not evaluated in previous trials. However, ongoing trials have included patients with CNS metastases (Table 3).

ICIs

Emerging evidence with clinical implications

ICIs are the standard treatment for patients with oncogene-negative advanced NSCLC, in which PD-L1 expression is the most robust biomarker. Monotherapy with PD-1/PD-L1 inhibitors is approved for patients with ≥ 50% PD-L1 expression. Additionally, combination therapy of PD-1/PD-L1 inhibitors and chemotherapy (bevacizumab or anti-CTLA-4 agents) has been approved as first-line therapy for patients with < 50% PD-L1 expression [76]. However, the response rate was higher and OS longer in patients treated with ICI plus chemotherapy compared with ICI monotherapy among patients with high PD-L1 expression [136]. The following section describes the recent clinical studies.

First, the novel PD-1/PD-L1 drugs provide additional treatment options compared with conventional ICIs [137]. In the EMPOWER-Lung 1 trial, which included patients with a PD-L1 tumor proportion score (TPS) ≥ 50%, first-line therapy with cemiplimab significantly prolonged the median PFS (8.2 vs. 5.0 months) and OS (21.9 vs. 13.0 months) [138]. The phase III EMPOWER-Lung 3 study enrolled advanced NSCLC patients irrespective of their PD-L1 expression level and found that cemiplimab plus chemotherapy was associated with clinically and statistically significant improvements in PFS and OS compared with chemotherapy alone [139]. The combination of toripalimab (CHOICE-01) and sugemalimab (GEMSTONE 302), developed in China, with chemotherapy prolonged the median PFS and OS in treatment-naive, advanced NSCLC patients [140, 141]. Second, new treatment combinations have been investigated to enhance the efficacy of the approved options. The combination of anti-PD-L1 and anti-TIGIT showed promising results. In the phase II CITYSCAPE trial, first-line treatment with tiragolumab (an anti-TIGIT antibody) plus atezolizumab improved the ORR and PFS in patients with metastatic NSCLC and a PD-L1 TPS ≥ 50% [142]. The phase III POSEIDON trial showed that first-line treatment with tremelimumab plus durvalumab and chemotherapy significantly prolonged PFS (6.2 vs. 4.8 months; p = 0.0003) and OS (14 vs. 11.7 months; p = 0.003) compared with chemotherapy alone [143]. The clinical benefit was highest in patients with non-squamous cell carcinoma and a PD-L1 TPS ≥ 1%. Third, patients with untreated or active brain metastases were often under-represented in previous clinical trials. In the single-arm phase II ATEZO-BRAIN trial, first-line treatment with atezolizumab plus chemotherapy exhibited similar systemic and intracranial response rates (47.5% vs. 40%) as assessed by the RECIST 1.1 and RANO-BM criteria, respectively. The median intracranial PFS was 6.9 months and the median OS 13.6 months, which were not affected by corticosteroid use [144]. Furthermore, the phase III ORIENT-31 trial, which administered a combination of anti-angiogenic therapy and chemotherapy, showed that ICIs are effective for oncogene-positive NSCLC patients who failed prior targeted therapy [145]. Sintilimab plus a bevacizumab biosimilar (IBI305) and chemotherapy prolonged the median PFS (6.9 vs. 4.3 months; p < 0.0001) and was well-tolerated in patients with EGFR-mutant NSCLC who progressed on previous EGFR-TKI therapy. A subgroup analysis in the IMpower150 trial revealed prolonged OS with a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel compared with a combination of bevacizumab, carboplatin, and paclitaxel in patients harboring EGFR mutations, including those with previous TKI failure. However, those results should be interpreted with caution [146]. Importantly, the first randomized phase III study, CheckMate722, showed negative results, with no significant improvement in PFS after nivolumab plus chemotherapy compared with chemotherapy alone in patients harboring EGFR mutations [147]. The aforementioned conflicting data suggest that an anti-angiogenic strategy has an important effect. Recent data have modified the complex treatment paradigm for NSCLC, which includes multiple treatment options, and PD-L1 expression remains an important biomarker (Fig. 2). The long-term outcomes of the new treatment options have confirmed their efficacy and safety. Thus, treatment selection should be careful and sometimes rely on clinical factors and patient preference [148].

Unresolved clinical issues

Despite the impressive efficacy of ICIs for NSCLC treatment, failure to respond due to primary or secondary resistance is common. The resistance mechanisms in human cancers include loss of neoantigens, defects in antigen presentation and interferon signaling, upregulation of immune inhibitory molecules, and exclusion of T cells [149–151]. Further translational and biological studies are needed to enhance the efficacy of ICI regimens and overcome resistance (Table 3).

Conclusions

Molecular-driven treatments that were previously only available for advanced-stage NSCLC have recently been shown to be effective for early- and locally advanced-stage disease. Recent studies have evaluated therapies that target a broader range of oncogenes to overcome drug resistance and treat patients who were previously excluded from clinical trials of advanced NSCLC. Emerging data are likely to impact future treatment guidelines and promote the use of personalized medicine by these ongoing trials. We envision that the treatment landscape will definitely evolve continuously, leading to improved survival and quality of life of patients with lung cancer.

Abbreviations

ADCs

Anti-body-drug conjugates

ALK

Anaplastic lymphoma kinase

ASTRO

American Society of Radiation Oncology

BRAFV600E

V-Raf murine sarcoma viral oncogene homolog B p.V600E

CNS

Central nervous system

ctDNA

Circulating tumor DNA

DFS

Disease-free survival

DS-8201

Trastuzumab deruxtecan

EFS

Even-free survival

EGFR

Epidermal growth factor receptor

ESTRO-EORTC

European Society for Therapeutic Radiology and Oncology–European Organisation for Research and Treatment of Cancer

FDA

Food and Drug Administration

HER2

Human epidermal growth factor receptor 2

HR

Hazard ratio

ICIs

Immune checkpoint inhibitors

KRASG12C

Kirsten rat sarcoma viral oncogene homolog G12C

LCT

Local consolidation therapies

MET14 skipping

Mesenchymal-epithelial transition factor exon 14 skipping

MRD

Molecular residual disease

NSCLC

Non-small cell lung cancer

NTRK1

Neurotrophic tyrosine receptor kinase

OS

Overall survival

pCR

Pathological complete response

PD-1/PD-L1

Programmed death 1/programmed death ligand 1

PFS

Progression-free survival

RAS

Rat sarcoma virus

RET

Rearranged during transfection

ROS1

C-ros oncogene 1

RTK

Receptor tyrosine kinase

TC

Tumor cells

T-DM1

Trastuzumab emtansine

TKIs

Tyrosine kinase inhibitor

TRK

Tyrosine receptor kinase

WCLC

World Conference of Lung Cancer

Author contributions

YLW and YQL designed the outline. SYML and MMZ drafted the manuscript. YLW, SYML and MMZ designed the figures and tables. YP and SYL offered professional suggestions to the manuscript. YLW and YQL provided the language editing. All authors read and approved the final manuscript.

Funding

This work was supported by National Natural Science Foundation of China (Grant No. 82202997 to S.Y.M. L.), China Postdoctoral Science Foundation (No. 2021M701422 to S.Y.M. L.), Key Lab System Project of Guangdong Science and Technology Department, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120 to Y.L.W.), and Guangdong Provincial People's Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province (Grant No. KJ012019426 to Y.L.W.), National Natural Science Foundation of China (Grant No. 82002413 to Dr. Si-Yang Liu).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Yi-Long Wu discloses the following personal financial interests: Consulting and advisory services, speaking engagements of Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Sanofi, MSD, and BMS. The other authors have no conflict of interest.